



**Clemens B Caspar**

**Contact**

Clemens B Caspar

## Publications (8)

Jörger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt A, Cantoni N, Caspar C, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). *Cancers (Basel)* 2022; 14

Ribi K, von Moos R, Caspar C, Mannhart M, von Burg P, Blum V, Bohanes P, Anchisi S, von Briel T, Zürrer-Härdi U, Cathomas R, Dietrich D, Schär C, Thürlimann B, Mark M. Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16). *BMC cancer* 2021; 21:182.

Mark M, Caspar C, Mannhart M, von Burg P, Blum V, Bohanes P, Anchisi S, von Briel T, Zürrer-Härdi U, Cathomas R, Dietrich D, Schär C, Ribi K, Thürlimann B, von Moos R. Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16). *J Bone Oncol* 2019; 21:100273.

Hitz F, Rondeau S, Berardi Vilei S, Eckhardt K, Enoiu M, Rothermundt C, Schmidt A, Krasniqi F, Mach N, Caspar C, Samaras P, Cairoli A, Fischer N, Pabst T, Zucca E, Mey U. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. *Br J Haematol* 2016

Stahel R, Caspar C, Eckhardt K, Schmid R, Aebersold D, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik L, Mordasini C, Zippelius A, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. *Lancet Oncol* 2015; 16:1651-8.

Pesce G, Bernhard J, Kotrubczik N, D'Addario G, Pilop C, Weber D, Bodis S, Pless M, Mayer M, Cathomas R, Peters S, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppli M, Caspar C, Fischer N, Anchisi S, Stupp R. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). *Eur J Cancer* 2011; 48:377-84.

von Moos R, Caspar C, Steiner R, Angst R, Inauen R, Schmieding K, Thürlimann B. Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes. *Onkologie* 2010; 33:447-50.

Koeberle D, Herrmann R, Mora O, Ruhstaller T, Strasser F, Beretta K, Mingrone W, Caspar C, Dietrich D, Gerber D, Borner M, Saletti P, Swiss Group for Clinical Cancer Research. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008; 26:3702-8.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)